Sodium glucose co-transporter 2 (SGLT2) inhibitors are a novel class of oral anti-hyperglycemic agents that are used in the treatment of type 2 diabetes mellitus. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.